Neuralstem Inc News - CUR

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COV...

RADNOR, Pa., March 19, 2021 (GLOBE NEWSWIRE) -- NeuroRx, Inc. announced the first patient in its P2/3 study...

Letter from Seneca Biopharma's Executive Chairman

Letter from Seneca Biopharma's Executive Chairman PR Newswire GERMANTOWN, Md., Sept. 2, 2020 GERMANTOWN, Md., Sept. 2, 2020 /PRNewswire/...

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering PR Newswire GERMANTOWN, Md., May 27, 2020 GERMANTOWN, Md...

Current Report Filing (8-k)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________...

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA PR Newswire GERMANTOWN, Md., Oct. 31, 2019 GERMANTOWN, Md., Oct. 31, 2019...

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto...

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto-Immune Diseases PR...

Current Report Filing (8-k)

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...

Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit PR Newswire GERMANTOWN, Md., Oct. 28...

Neuralstem Becomes Seneca Biopharma

Neuralstem Becomes Seneca Biopharma PR Newswire GERMANTOWN, Md., Oct. 28, 2019 GERMANTOWN, Md., Oct. 28, 2019...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Amended Statement of Beneficial Ownership (3/a)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL...

Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Neuralstem Inc (CUR)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CUR News

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COV...

Letter from Seneca Biopharma's Executive Chairman

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering

Current Report Filing (8-k)

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto...

Current Report Filing (8-k)

Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

Neuralstem Becomes Seneca Biopharma

Initial Statement of Beneficial Ownership (3)

Amended Statement of Beneficial Ownership (3/a)

Initial Statement of Beneficial Ownership (3)

Amended Statement of Changes in Beneficial Ownership (4/a)

Amended Statement of Changes in Beneficial Ownership (4/a)

CUR Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Neuralstem Inc (CUR) News

Neuralstem Inc (CUR)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CUR News

FeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent

NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COV...

Letter from Seneca Biopharma's Executive Chairman

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering

Current Report Filing (8-k)

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto...

Current Report Filing (8-k)

Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership Summit

Neuralstem Becomes Seneca Biopharma

Initial Statement of Beneficial Ownership (3)

Amended Statement of Beneficial Ownership (3/a)

Initial Statement of Beneficial Ownership (3)

Amended Statement of Changes in Beneficial Ownership (4/a)

Amended Statement of Changes in Beneficial Ownership (4/a)

CUR Discussion

Your Recent History